Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature

Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Reka Gabriela, Pawlak Angelika, Machowiec Piotr, Maksymowicz Marcela, Piecewicz-Szczesna Halina
Formato: article
Lenguaje:EN
Publicado: Sciendo 2021
Materias:
R
Acceso en línea:https://doaj.org/article/8d36b220768b4d5a88654c0f351f3369
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares